Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Work In Process (2016 - 2025)

Corcept Therapeutics' Work In Process history spans 10 years, with the latest figure at $13.7 million for Q4 2025.

  • For Q4 2025, Work In Process rose 75.93% year-over-year to $13.7 million; the TTM value through Dec 2025 reached $13.7 million, up 75.93%, while the annual FY2025 figure was $13.7 million, 75.93% up from the prior year.
  • Work In Process for Q4 2025 was $13.7 million at Corcept Therapeutics, down from $14.2 million in the prior quarter.
  • Across five years, Work In Process topped out at $14.9 million in Q1 2021 and bottomed at $6.7 million in Q2 2023.
  • The 5-year median for Work In Process is $10.0 million (2022), against an average of $10.4 million.
  • The largest annual shift saw Work In Process crashed 41.28% in 2023 before it surged 82.86% in 2025.
  • A 5-year view of Work In Process shows it stood at $11.4 million in 2021, then tumbled by 31.64% to $7.8 million in 2022, then increased by 5.19% to $8.2 million in 2023, then fell by 5.39% to $7.8 million in 2024, then skyrocketed by 75.93% to $13.7 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Work In Process are $13.7 million (Q4 2025), $14.2 million (Q3 2025), and $11.8 million (Q2 2025).